By admin 
The "Most Favored Nation" (MFN) model, a policy concept that has traversed a tumultuous legal and political path since its inception during Trump’s first term, operates on a deceptively simple premise. It mandates that the price the U.S. government pays for certain prescription drugs cannot exceed the lowest price paid by a "peer" country—typically defined as a member of the G7 or other high-income OECD nations like Canada, Germany, France, and Japan. For decades, the United States has shouldered the lion’s share of global pharmaceutical research and development costs, often paying two to three times more for the same medications than European or Asian counterparts. The administration’s latest move seeks to dismantle this pricing disparity by using the leverage of Medicaid’s massive purchasing power.
According to the reports from Daniel Payne and Elaine Chen, the nine confirmed deals target a range of therapeutic areas, including chronic conditions like Type 2 diabetes, autoimmune disorders, and advanced respiratory illnesses. These drugs represent some of the highest-cost line items for state Medicaid budgets, which have been strained by the rising prevalence of chronic disease and the introduction of high-cost biologics. By pegging the Medicaid reimbursement rate to international benchmarks, the administration estimates it could save federal and state governments upwards of $15 billion over the next five years.
However, the mystery of the "tenth deal" remains the primary focus for K Street lobbyists and pharmaceutical executives. Sources close to the negotiations suggest that the missing deal involves a blockbuster immunotherapy drug used to treat late-stage melanoma and non-small cell lung cancer. This particular drug has been a point of contention between the Department of Health and Human Services (HHS) and the manufacturer for months. The manufacturer has reportedly threatened to pull the drug from certain markets or limit supply if the MFN pricing is enforced, citing a potential "chilling effect" on future innovation. The omission of this drug from the official announcement suggests that negotiations may have reached a stalemate or that the administration is holding it back as a strategic lever for a separate policy objective.
The broader context of these MFN deals cannot be overstated. Since the 2020 executive orders that first introduced the concept, the pharmaceutical industry has fought the MFN model with every legal tool at its disposal. Organizations like the Pharmaceutical Research and Manufacturers of America (PhRMA) have argued that the policy is an unconstitutional overreach of executive authority and a violation of the Administrative Procedure Act. They contend that by importing foreign price controls, the U.S. is essentially importing the rationing and delayed access to care that characterize many socialized medicine systems.
"The MFN model is a blunt instrument that ignores the complexities of the U.S. healthcare market," a spokesperson for a major pharmaceutical trade group stated in response to the announcement. "By forcing prices down to levels seen in countries with vastly different economic structures and clinical priorities, the administration is jeopardizing the very R&D ecosystem that produced the COVID-19 vaccines and continues to turn cancer into a manageable condition. This isn’t just about pricing; it’s about the future of American medical leadership."
Conversely, patient advocacy groups and fiscal conservatives have found rare common ground in supporting the MFN approach. Proponents argue that the current system allows pharmaceutical companies to exploit American taxpayers, who often fund the early-stage basic research through the National Institutes of Health (NIH) only to be charged exorbitant prices for the resulting commercial products. The MFN deals are seen as a necessary correction to a market failure where the U.S. acts as the "world’s pharmacy" without receiving any of the bulk-purchasing benefits enjoyed by other nations.
The focus on Medicaid is particularly strategic. Unlike Medicare, where the Inflation Reduction Act (IRA) has already established a framework for drug price negotiations, Medicaid has historically relied on a complex system of rebates and "best price" rules. By layering MFN requirements onto the Medicaid program, the administration is effectively bypassing some of the legislative hurdles that have slowed Medicare negotiations. State governors, many of whom are grappling with balanced-budget requirements, have largely welcomed the prospect of reduced pharmacy spend, though some express concern about potential litigation delaying the actual realization of these savings.
The technical implementation of these nine—or ten—deals involves a sophisticated "basket" approach. HHS will track the Net Price of the targeted drugs in a selection of peer countries, adjusting for currency fluctuations and local rebates where data is available. The MFN price is then set as the ceiling for Medicaid reimbursement. If a manufacturer refuses to offer this price, they face significant penalties or the risk of losing "preferred" status on state formularies, which would effectively shut them out of a market that serves over 80 million Americans.
The economic implications are vast. Wall Street analysts have already begun downgrading several biotech stocks in anticipation of the revenue hits. There is also the "spillover effect" to consider. While these deals are technically limited to Medicaid, private insurers often use government pricing as a benchmark for their own negotiations. If Medicaid successfully secures international parity, private payers like UnitedHealthcare and Aetna will undoubtedly demand similar terms, potentially leading to a wholesale restructuring of drug pricing across the entire U.S. healthcare system.
Expert perspectives on the MFN model remain deeply divided. Some economists point out that while the policy lowers costs for the government, it may lead to "price convergence" globally. If pharmaceutical companies know that a low price in Greece or Portugal will trigger a mandatory price cut in the massive U.S. market, they may simply raise prices in those smaller countries or refuse to launch new drugs there altogether. This could lead to a global increase in drug prices, ironically harming the very "peer countries" the U.S. is trying to emulate.
"We have to be careful what we wish for," said a professor of health policy at Johns Hopkins University. "If the U.S. stops paying the premium that supports global innovation, where does that money come from? Either innovation slows down, or other countries have to start paying more. The MFN model assumes that the rest of the world’s prices are the ‘correct’ ones, but those prices only exist because the U.S. market currently absorbs the fixed costs of drug development."
Despite these warnings, the political momentum behind MFN appears unstoppable in the current climate. With the 2026 midterm elections approaching, the administration is keen to demonstrate tangible progress on kitchen-table issues like healthcare costs. The "Nine, or 10" deals represent a high-stakes gamble that the pharmaceutical industry will ultimately blink and accept lower margins rather than lose access to the American patient base.
As the industry waits for the "missing" tenth deal to be clarified, the focus shifts to the courts. It is almost certain that by the end of the week, several of the manufacturers involved in the nine confirmed deals will file for preliminary injunctions to block the implementation of the MFN prices. These legal battles will likely center on whether the executive branch has the authority to fundamentally alter Medicaid’s reimbursement structure without explicit new authorization from Congress.
In the interim, the news has left many in the beltway wondering about the "Hermès-esque" lifestyle mentioned in the social circles of New York and Baltimore bartenders—a stark contrast to the gritty, high-stakes negotiations occurring in the halls of HHS. While some may be sipping spritzes out of designer glass purses, the healthcare world is bracing for a hangover that could last years. The MFN policy isn’t just a change in pricing; it’s a paradigm shift in how the United States values medical innovation versus fiscal sustainability. Whether the tally ends at nine or ten, the message is clear: the era of American "exceptionalism" in drug pricing is under direct and sustained assault. The coming months will determine if this policy becomes a permanent fixture of the American healthcare landscape or if it will be dismantled by the same legal and economic pressures that have thwarted similar efforts in the past. For now, the pharmaceutical world remains on edge, watching for the announcement of that tenth deal, which could be the most significant—and controversial—one yet.
